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Background: Patient adherence to cardioprotective medications improves outcomes
of acute coronary syndrome (ACS), but few adherence-enhancing interventions have
been tested in low-income and middle-income countries.
Objectives: We aimed to assess whether a pharmacist-led intervention enhances
medication adherence in patients with ACS and reduces mortality and hospital
readmission.
Methods: We conducted a randomized controlled trial in Vietnam. Patients with ACS
were recruited, randomized to the intervention or usual care prior to discharge, and
followed 3 months after discharge. Intervention patients received educational and
behavioral interventions by a pharmacist. Primary outcome was the proportion of
adherent patients 1 month after discharge. Adherence was a combined measure of
self-reported adherence (the 8–item Morisky Medication Adherence Scale) and obtaining
repeat prescriptions on time. Secondary outcomes were (1) the proportion of patients
adherent to medication; (2) rates of mortality and hospital readmission; and (3) change
in quality of life from baseline assessed with the European Quality of Life Questionnaire
– 5 Dimensions – 3 Levels at 3 months after discharge. Logistic regression was used to
analyze data. Registration: ClinicalTrials.gov (NCT02787941).
Results: Overall, 166 patients (87 control, 79 intervention) were included (mean age
61.2 years, 73% male). In the analysis excluding patients from the intervention group
who did not receive the intervention and excluding all patients who withdrew, were lost
to follow-up, died or were readmitted to hospital, a greater proportion of patients were
adherent in the intervention compared with the control at 1 month (90.0% vs. 76.5%;
adjusted OR = 2.77; 95% CI, 1.01–7.62) and at 3 months after discharge (90.2% vs.
77.0%; adjusted OR = 3.68; 95% CI, 1.14–11.88). There was no significant difference
in median change of EQ-5D-3L index values between intervention and control [0.000
(0.000; 0.275) vs. 0.234 (0.000; 0.379); p = 0.081]. Rates of mortality, readmission, or
both were 0.8, 10.3, or 11.1%, respectively; with no significant differences between the
2 groups.
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Conclusion: Pharmacist-led interventions increased patient adherence to medication
regimens by over 13% in the first 3 months after ACS hospital discharge, but not quality
of life, mortality and readmission. These results are promising but should be tested in
other settings prior to broader dissemination.
Keywords: acute coronary syndrome, medication adherence, pharmacist-led intervention, randomized controlled
trial, Vietnam
INTRODUCTION
In patients with ischemic heart diseases (IHDs), medication
adherence improves health outcomes and reduces costs (Horne
et al., 2005; Simpson et al., 2006; Bitton et al., 2013; Chowdhury
et al., 2013). IHDs are the world’s biggest killer, accounting
for 8.9 million deaths in 2015 (GBD 2015 DALYs and HALE
Collaborators, 2016; World Health Organization, 2017b). Over
80% of those occur in low-income and middle-income countries
(LMICs), such as Vietnam (Dugani and Gaziano, 2016). IHDs
comprise stable angina and acute coronary syndrome (ACS)
which is the dominant cause of IHD deaths (Moran et al., 2014).
Survivors of ACS have an increased risk of recurrent infarctions
and their annual death rate is up to six times higher than in
healthy people of the same age (World Health Organization,
2017a). A substantial proportion of people are non-adherent to
cardiovascular medications (Chowdhury et al., 2013), ranging
from 14 to 46% in patients discharged from the hospital after an
ACS, higher rates are especially reported for LMICs (Bowry et al.,
2011; Akeroyd et al., 2015).
Many types of interventions to improve medication adherence
in patients with IHDs have been developed. Of these, a
substantial proportion was driven by pharmacists (Santo et al.,
2016). In addition to medication dispensing, pharmacists
can provide medication education and disease management
for patients (Kang et al., 2016). Systematic reviews on the
effect of pharmacists (Cai et al., 2013; Kang et al., 2016)
have shown a positive impact on outcomes in patients with
IHDs. In Vietnam, the extended clinical role of pharmacists
in improving the medicine use process has been recognized
(Nguyen et al., 2014). However, there is a lack of research
on pharmacist-led interventions in ACS which is one of the
leading causes of deaths in Vietnam (Vietnam Ministry of Health,
2013). Therefore, we aimed to assess whether a pharmacist-
led multifaceted intervention enhances medication adherence




We conducted a randomized, controlled trial with concealment
of allocation and blinded outcome assessment at the Heart
Institute of Ho Chi Minh City in Vietnam. The study
was approved by the institutional biomedical research
ethics committee and was registered at ClinicalTrials.gov
(NCT02787941). Written informed consent was obtained from
each study participant.
Study Setting, Population, and
Recruitment
The Heart Institute of Ho Chi Minh City was created in 1992
with the mission to offer high-quality care to Vietnamese patients
suffering from heart diseases. Since 1992, over 25,000 patients
with complicated heart problems have been treated. In general,
the heart institute nowadays performs heart surgeries to the
same level as done in high-income countries. Furthermore, the
institute runs cooperation programs to transfer technology and
heart surgery techniques to provincial hospitals (Tuoi Tre News,
2015).
At the study hospital usual care for patients with ACS was
as follows. After discharge, patients with ACS were followed
up at a public or private health care center as an outpatient.
Appointments were scheduled every two to four weeks to assess
health status and progress of the disease, issue a new prescription
for medication, and schedule the next appointment. The patient
had their medication dispensed at the hospital pharmacy free of
charge (if they have a social health insurance) or at any private
pharmacy with payment. Social health insurance in Vietnam
is the national insurance coverage paid by the Vietnamese
government for medical and surgical expenses incurred by
the insured. The contributions are paid by the government
completely or partially. Prescriptions might be redeemed up until
the date of the next appointment. This is the normal process of
care for a patient after an ACS in Vietnam.
Recruitment was between 1st November 2015 and 31st
October 2016 in Ho Chi Minh City. The follow-up ended on 31st
January 2017. Patients admitted with ACS as the primary reason
for hospital admission were screened for eligibility. We included
patients who survived during hospitalization with one of the
following diagnoses according to the coding of the International
Classification of Diseases, 10th revision (ICD-10): unstable
angina (I20.0), acute myocardial infarction (I21) or subsequent
myocardial infarction (I22) (World Health Organization, 2016).
We excluded patients who (1) participated already in another
medication adherence study; (2) were discharged without a
prescription; (3) had considerable cognitive impairment; (4)
were unable to communicate in Vietnamese; (5) were unable to
identify their own medications; (6) could not provide a telephone
number; or (7) stayed in the hospital three days or less (because
this period was too short for recruitment, baseline data collection,
and intervention).
Randomization and Intervention
Randomization was performed in advance using an online
random number generator (randomization.com). Eligible
patients were stratified by age (<65 and 65 years or higher) and
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sex (male and female), and were randomized into two parallel
groups in a 1:1 ratio via block technique with random permuted
blocks of 2, 4, or 6 patients. The control group received usual
care. The intervention consisted of a pharmacist-delivered
multifaceted intervention in addition to usual care. Investigators
who performed patient recruitment had been concealed the
sequence until the intervention was assigned. Outcome assessors
were blinded; patients and pharmacists performing interventions
could not be blinded due to the nature of the intervention.
The multifaceted intervention comprised two counseling
sessions. At the first counseling, a pharmacist performed a 30-
min in-person counseling within 1 week before discharge
including: (1) assessment and giving advice on basic
knowledge of ACS: definition, risk factors, possible cardiac
events, and prevention; (2) assessment of past experiences
of using medications, encouragement and tailored advice;
(3) providing medication aids including pill organizer and
drug information leaflet; (4) teaching back and correcting
misunderstanding (Appendix 1). At the second counseling,
the pharmacist performed a 30-min telephone counseling
within 2 weeks after discharge including: (1) assessment of
general and medication-related issues patients concerning;
(2) encouragement and tailored advice; (3) teaching back and
correcting misunderstanding (Appendix 2).
Data Collection
The process of data collection and management at baseline
and during the follow-up period was summarized in Appendix
3. We collected data using the instruments as follows: the
eight-item Morisky Medication Adherence Scale (MMAS-8), the
European Quality of Life Questionnaire – 5 Dimensions – 3
Levels (EQ-5D-3L), the Beliefs about Medicines Questionnaire –
Specific (BMQ-S), the Mini–Mental State Examination (MMSE),
and three predefined data collection forms. The MMAS-8 is
an 8-item questionnaire designed to facilitate identification
of barriers to and behaviors associated with adherence to
medication. Response choices are yes/no for items 1 through
7, and a 5-point Likert response scale for the last item
(Morisky et al., 2008). The EQ-5D-3L comprises the following 5
dimensions: mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression. Each dimension has 3 levels: no problem,
some problems, and extreme problems (EuroQol Group, 2015).
The BMQ Specific assesses patients’ beliefs about the particular
medications prescribed for them, comprising two subscales:
Specific Necessity and Specific Concerns. Each item of the BMQ
subscales is scored on a 5-point Likert scale ranging from 1
(strongly disagree) to 5 (strongly agree) (Horne et al., 1999).
The MMSE is a 30-point scale that assesses several domains
of cognition including memory, orientation, and arithmetic.
A lower score indicates greater cognitive impairment (Folstein
et al., 1975; Leggett et al., 2013). Data collection form 1 included
patients and their caregivers’ contact information, education
level, marital status, and ability to identify medications. Data
collection form 2 included patients’ baseline characteristics:
demographic characteristics, coronary artery disease risk factors,
medical history and comorbidities, discharge diagnoses, in-
hospital invasive procedures, and discharge medications. Data
collection form 3 included the information of complying with
medical visits and clinical adverse events.
Study Outcomes
The primary outcome was predefined in the protocol as
the proportion of patients who adhered to cardioprotective
medications at 1 month after discharge. We defined patient
adherence to cardioprotective medications as returning for their
scheduled outpatient appointments (complying with medical
visits) and having an MMAS-8 score of six or higher at 1-month
follow-up. Complying with medical visits was determined based
on patient reports and medical records. Patients being two days
or later for their outpatient appointment were considered as non-
compliant. We included this as a measure of patient adherence
as patients had to return for their appointments to obtain their
follow-up prescriptions on time.
The secondary outcomes were (1) the proportion of patients
who adhered to cardioprotective medications at 3 months after
discharge; (2) the proportion of patients readmitted to hospital of
any cause at 3 months; (3) the proportion of patients dying of any
cause at 3 months; and (4) change in quality of life from baseline
assessed with EQ-5D-3L at 3 months.
Analysis
For sample size calculations, we assumed 70% adherence
(Nguyen et al., 2016), alpha = 0.05, and beta = 0.20.
Prior pharmacist-led interventions had achieved absolute
improvements in adherence of 15% to 35% (Ho et al., 2014;
Lourenco et al., 2014; Oliveira-Filho et al., 2014). In order to
detect a 20% difference in adherence between the control and
intervention groups and to account for 20% loss to follow-up, we
enrolled at least 152 patients (76 per group).
We performed two analyses. Analysis 1 included all patients
excluding patients from the intervention group who did not
receive the intervention and excluding all patients who withdrew,
were lost to follow-up, died or were readmitted to hospital.
Analysis 2 included all patients who survived and were not
readmitted to hospital using multiple imputations to impute
missing outcomes of patients who discontinued and were lost to
follow-up. Regression models with five iterations were performed
to produce five versions of the dataset, each containing its own set
of imputed values. The parameter estimates for all of the imputed
datasets were pooled, providing estimates that are generally more
accurate than they would be with only one imputation.
Data were presented as absolute numbers, percentages, means
with standard deviations (SDs), or medians with interquartile
ranges (IQRs) as appropriate. Characteristics, quality of life,
and mortality/readmission to hospital of patients randomized
to the intervention and control groups were compared using
Chi-square test or Fisher’s exact test for all categorical variables
and Independent t-test or Mann–Whitney test for all continuous
variables. Univariable and multivariable logistic regression
models were used to estimate the odds ratio (OR) with 95%
confidence interval (CI) of the intervention for adherence
outcomes. The change in quality of life which was assessed
using McNemar test (categorical) and Wilcoxon signed rank test
(continuous). All tests were two-sided. P-values of 0.05 or less
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were considered statistically significant. Analyses were performed
using the Statistical Package for the Social Sciences, version 20th
(SPSS 20).
RESULTS
Of 577 patients assessed for eligibility, 166 (28.8%) patients were
included; 195 (33.8%) patients were excluded due to exclusion
criteria; and 216 (37.4%) declined to participate. Of 166 patients
included, 87 were randomized to the control condition and
79 to the intervention condition. A total of 153 (92.2%) and
126 (75.9%) completed the 1-month and 3-month follow-ups,
respectively. Six patients in the intervention group did not
receive the intervention due to severe illness. Two patients
who discontinued to participate refused to provide the reason.
Reasons for loss to follow-up of 32 patients were not available
because we could not contact patients or their relatives (Figure 1).
The mean age (SD) was 61.2 (9.6) years, 72.3% were males,
and 84.3% had social health insurance. The majority of patients
had a discharge diagnosis of non-ST-segment elevation ACS
(75.3%) and more than two comorbidities (53.6%). During
the hospitalization, median (IQR) of the EQ-5D-3L index
value was 0.726 (0.573; 1) and 54.2% patients underwent
percutaneous coronary intervention (PCI). No differences in the
characteristics of demographics, coronary artery disease (CAD)
risk factors, medical history, comorbidities, type of ACS, in-
hospital revascularization, discharge medications, BMQ Specific
scoring, and EQ-5D-3L scoring were found among groups
(Table 1).
In Analysis 1, a greater proportion of patients were adherent
in the intervention group compared with the control group at
1 month (90.0% vs. 76.5%; adjusted OR = 2.77; 95% CI, 1.01–
7.62) and at 3 months after discharge (90.2% vs. 77.0%; adjusted
OR = 3.68; 95% CI, 1.14–11.88) (Tables 2, 3). There was no
covariate associated with adherence at 1 month; but at 3 months
patients who were male (adjusted OR = 0.16; 95% CI, 0.03–0.83)
or who had more concerns about medicines (higher scores of
BMQ Specific Concern) (adjusted OR = 0.89; 95% CI, 0.79–0.99)
were less likely to be adherent. Description of non-adherence was
presented in Appendix 4.
There was a significant increase in median EQ-5D-3L index
value from baseline to 3 months in both groups: control [0.686
(0546.; 1) vs. 1 (0.726; 1); p < 0.001] and intervention [0.766
(0.645; 1) vs. 1 (0.726; 1); p = 0.004]. But there was no significant
difference in median change of EQ-5D-3L index values between
FIGURE 1 | Flowchart of the study population. ACS, acute coronary syndrome; aPatients who were only excluded from the analysis of adherence 1 month after
discharge.
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TABLE 1 | Baseline characteristics of the study population.
Group
Patient characteristic Overall (N = 166) n (%) Control (N = 87) n (%) Intervention (N = 79) n (%) p-valuea
Demographics and general characteristics
Age, mean (SD) 61.2 (9.6) 59.8 (8.8) 62 (8.4) 0.221b
Ages ≥65 57 (34.3) 28 (32.2) 29 (36.7) 0.540
Male 120 (72.3) 59 (67.8) 61 (77.2) 0.177
Social health insurance 140 (84.3) 73 (83.9) 67 (84.8) 0.873
Education grade ≥6 132 (79.5) 66 (75.9) 66 (83.5) 0.221
Married 150 (90.4) 75 (86.2) 75 (94.5) 0.057
CAD risk factors
CAD family history 3 (1.8) 2 (2.3) 1 (1.3) 1.000d
Hypertension 121 (72.9) 58 (66.7) 63 (79.7) 0.058
Diabetes 45 (27.1) 22 (25.3) 23 (29.1) 0.580
Dyslipidemia 41 (24.7) 20 (23.0) 21 (26.6) 0.592
Smoking 71 (43.0) 34 (39.5) 37 (46.8) 0.344
Medical history and comorbidities
Prior MI/stroke 22 (13.3) 11 (12.6) 11 (13.9) 0.808
Prior PCI/CABG 29 (17.5) 16 (18.4) 13 (16.5) 0.743
Heart failure 4 (2.4) 3 (3.4) 1 (1.3) 0.622d
Renal failure 15 (9.0) 7 (8.0) 8 (10.1) 0.641
Peptic ulcer 50 (30.1) 26 (29.9) 24 (30.4) 0.945
Asthma/COPD 6 (3.6) 3 (3.4) 3 (3.8) 1.000d
Comorbidities ≥2 89 (53.6) 42 (48.3) 47 (59.5) 0.148
Type of ACS
NSTEACS 125 (75.3) 63 (72.4) 62 (78.5) 0.365
STEACS 41 (24.7) 24 (27.6) 17 (21.5)
In-hospital revascularization and discharge medications
PCI/CABG 90 (54.2) 45 (51.7) 45 (57.0) 0.499
Antiplatelet agent 163 (98.2) 84 (96.6) 79 (100) 0.247d
Beta blocker 114 (68.7) 62 (71.3) 52 (65.8) 0.450
ACEI/ARB 158 (95.2) 83 (95.4) 75 (94.9) 1.000d
Statin 161 (97.0) 85 (97.7) 76 (96.2) 0.670d
Number of medications, mean (SD) 8.0 (1.9) 7.9 (2.0) 8.1 (1.7) 0.533b
BMQ Specific scoring
BMQ Specific Necessity, median (IQR) 23 (21; 25) 21 (19; 23) 20 (14; 24) 0.936c
BMQ Specific Concern, median (IQR) 11 (9; 14) 10 (9; 13) 12 (9; 15) 0.292c
EQ-5D-3L scoring
Mobilitye 52 (31.3) 33 (37.9) 19 (24.1) 0.054
Self-caree 30 (18.1) 15 (17.2) 15 (19.0) 0.770
Usual activitiese 33 (19.9) 18 (20.7) 15 (19.0) 0.784
Pain/ discomforte 62 (37.3) 35 (40.2) 27 (34.2) 0.421
Anxiety/ depressione 65 (39.2) 33 (37.9) 32 (40.5) 0.734
EQ-5D-3L index value, median (IQR) 0.726 (0.573; 1) 0.694 (0.549; 1) 0.766 (0.605; 1) 0.111c
ACEI/ARB, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers; BMQ, the Beliefs about Medicines Questionnaire; CAD, coronary artery disease;
COPD, chronic obstructive pulmonary disease; EQ-5D-3L, the European Quality of Life Questionnaire – 5 Dimensions – 3 Levels; IQR, interquartile range; NSTEACS,
non-ST elevation acute coronary syndrome; PCI/CABG, percutaneous coronary intervention/coronary artery bypass grafting; STEACS, ST evaluation acute coronary
syndrome. aUsing Chi-square test if other tests were not mentioned. bUsing Independent t-test. cUsing Mann–Whitney test. dUsing Fisher’s exact test. ePatients reported
having problems with each dimension of EQ-5D-3L.
control and intervention [0.234 (0.000; 0.379) vs. 0.000 (0.000;
0.275); p = 0.081] (Table 4).
The proportion of patients dying, being readmitted to
hospital, and both at 3 months was 0.8, 10.3, and 11.1%,
respectively. These were not significantly different between the
2 groups (Table 5).
In Analysis 2, a greater proportion of patients were
adherent in the intervention group compared with the
control group at 1 month (adjusted OR = 2.35; 95% CI,
1.00–5.52), but no significant differences were found
at 3 months (adjusted OR = 1.90; 95% CI, 0.86–4.22)
(Tables 2, 3).
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Univariable analysis Multivariable analysisb
OR 95% CI p OR 95% CI p
Analysis 1a (N = 68 control and 60 intervention patients)
Adherence 52 (76.5) 54 (90.0) 13.5 (7; 26.4) 2.77 1.01–7.62 0.043 2.77 1.01–7.62 0.049
Non-adherence 16 (23.5) 6 (10.0)
Analysis 2 (N = 83 control and 71 intervention patients)
Adherence 57 (68.7) 59 (83.1) 15 (1.6; 28.4) 2.32 1.00–5.36 0.049 2.35 1.00–5.52 0.050
Non-adherence 26 (31.3) 12 (16.9)
Abbreviations: CI, confidence interval; OR, odds ratio. aSample of Analysis 1 excluding patients who were not measured adherence at 1 month. bUsing multivariable
backward stepwise logistic regression models. Variables entered at the first step: intervention status, age, gender, health insurance, education grade ≥6, marital status,
number of comorbidities ≥2, type of ACS, BMQ Specific Necessity and Concern scores, and PCI/CABG.








Univariable analysis Multivariable analysisa
OR 95% CI p OR 95% CI p
Analysis 1 (N = 61 control and 51 intervention patients)
Adherence 47 (77.0) 46 (90.2) 13.1 (−5; 26.8) 2.74 0.91–8.23 0.065 3.68 1.14–11.88 0.030
Non-adherence 14 (33.0) 5 (9.8)
Analysis 2 (N = 80 control and 70 intervention patients)
Adherence 52 (65.0) 53 (75.7) 10.1 (−5.9; 26.0) 1.71 0.81–3.62 0.158 1.90 0.86–4.22 0.115
Non-adherence 27 (35.0) 17 (24.3)
Abbreviations: CI, confidence interval; OR, odds ratio. aUsing multivariable backward stepwise logistic regression models. Variables entered at the first step: intervention
status, age, gender, health insurance, education grade ≥ 6, marital status, number of comorbidities ≥ 2, type of ACS, BMQ Specific Necessity and Concern scores, and
PCI/CABG.
TABLE 4 | Changes in quality of life from baseline at the first 3 months after discharge.
EQ-5D-3L Baselinea 3-montha Comparisonc
Controlb
N = 60, n (%)
Interventionb
N = 49, n (%)
Controlb
N = 60, n (%)
Interventionb
N = 49, n (%)
p1 p2
Mobility No problems 37 (61.7) 38 (77.6) 51 (85.0) 41 (83.7) 0.004 0.581
Problems 23 (38.3) 11 (22.4) 9 (15.0) 8 (16.3)
Self-care No problems 50 (83.3) 43 (87.8) 55 (91.7) 47 (93.9) 0.227 0.289
Problems 10 (16.7) 6 (12.2) 5 (8.3) 2 (4.1)
Usual activities No problems 46 (76.7) 41 (83.7) 55 (91.7) 46 (93.9) 0.049 0.180
Problems 14 (23.3) 8 (16.3) 5 (8.3) 3 (6.1)
Pain/discomfort No problems 37 (61.7) 34 (69.4) 38 (63.3) 36 (73.5) 1.000 0.832
Problems 23 (38.3) 15 (30.6) 22 (36.7) 13 (26.5)
Anxiety/depression No problems 35 (58.3) 30 (61.2) 45 (75.0) 36 (73.5) 0.052 0.238
Problems 25 (41.7) 19 (38.8) 15 (25.0) 13 (26.5)
EQ-5D-3L index value, median (IQR) 0.686 (0546.; 1) 0.766 (0.645; 1) 1 (0.726; 1) 1 (0.726; 1) <0.001d 0.004d
Change of EQ-5D-3L index values, median (IQR) NA NA 0.234 (0.000; 0.379) 0.000 (0.000; 0.275) p3 = 0.081
Abbreviations: EQ-5D-3L, the European Quality of Life Questionnaire - 5 Dimensions - 3 Levels; IQR, interquartile range, NA, not applicable. p1 Comparison between
baseline and 3-month EQ-5D-3L scores of the control group. p2 Comparison between baseline and 3-month EQ-5D-3L scores of the intervention group. p3 Comparison
between changes from baseline of EQ-5D-3L index values of the control and intervention groups at the first 3 months after discharge. aNo difference in each dimension
and index value of EQ-5D-3L between control and intervention groups at baseline or the first 3 months after discharge. bSample size of patients who reported EQ-5D-3L
at both baseline and the first 3 months after discharge. cUsing McNemar test if other tests were not mentioned. dUsing Wilcoxon signed rank test.
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TABLE 5 | Rates of mortality and readmission to hospital within the first 3 months after discharge.
Group
Adverse event Overall N = 126, n (%) Control N = 68, n (%) Intervention N = 58, n (%) p-valuea
Mortality 1 (0.8) 1 (1.5) 0 (0) 1.000b
Readmission 13 (10.3) 6 (8.8) 7 (12.1) 0.551
Mortality/Readmission 14 (11.1) 7 (10.3) 7 (12.1) 0.752
aUsing Chi-square test if other tests were not mentioned. bUsing Fisher’s exact test.
DISCUSSION
Principal Findings
Our intervention comprising pharmacist-led medication
counseling and tailoring, patient education, and providing
medication aids enhanced the proportion of adherent patients
by over 13% in the first 3 months after discharge. The potential
factors associated with poor adherence were male gender and
patients’ concerns about medicines. There was no statistically
significant improvement in quality of life, mortality and
readmission to hospital over the 3 months of the study.
Strengths and Weaknesses of the Study
This is the first study to carry out an in-depth assessment
of the pharmacist-led intervention that contributes to the
improvement on adherence to cardioprotective medications
in patients with ACS in Vietnam. A strength of our study
was the high-quality design, e.g., allocation concealment to
keep trial investigators unaware of upcoming allocations and
blinded outcome assessment to avoid bias in estimated treatment
effects. The MMAS-8 was translated, cross-culturally adapted and
validated as a reliable tool to measure medication adherence
in Vietnamese patients (Nguyen et al., 2015). In considering
replication and expansion of this intervention in further large-
scale studies or in clinical practice, there are several lessons about
process and evaluation that may be useful. Our intervention
included multiple components, all of which have been shown
to improve adherence to medication regimens among patients
with cardiovascular diseases (Cutrona et al., 2010; Ho et al.,
2014). While our study was conducted in a specialized hospital,
none of the components was unique to it and can be replicated
in other health care settings. In our study, a pharmacist
counseled prehospital and post-hospital medications within two
weeks of discharge and provided patients with medication aids.
The feasibility of this pharmacist-led intervention must be
highlighted, as it does not depend on expensive materials or
equipment to be performed. In fact, the role of pharmacists
in Vietnam has been expanding from dispensing medications
to providing services about medication management to support
rational use of medicine (Vo et al., 2013). With an increasing
number of patients needing the long-term use of secondary
prevention medications for treatment of IHDs as well as other
chronic diseases, findings of our study may encourage a closer
cooperation of physicians with clinical pharmacists in order to
make optimal use of available resources and achieve expected
therapeutic outcomes in treatment for these patients.
Several issues in our study should be considered. First, we
conducted the study in a selected single center setting in the
urban region of Vietnam. Further research that includes more
participants from multiple centers is needed to confirm the
present results. Larger studies that include cost-effectiveness
analyses are also needed. Second, the duration of the intervention
might be too short to change a complex behavior such as
adherence to taking medication. While we have seen changes
in behavior in the expected direction in the intervention
group of our study, we might have seen larger effects if
the intervention had been repeated more often. Furthermore,
studies with longer follow-up are needed to assess adherence
on a long-term basis. Third, findings of the study might be
difficult to compare to those of other studies due to the
unique criteria for primary outcome measurement. Fourth, the
study was powered to detect a difference of 20 percentage
points in adherence. Although the pharmacist-led intervention
had an effect on improved adherence, the effect size was
smaller. This generated the wider confidence intervals of the
estimated odds ratios. Larger studies are needed to confirm
the efficacy and value of interventions with the small effect
size. Fifth, we measured patient adherence using the MMAS-
8 which might be biased by inaccurate patient recall or patient
giving socially desirable responses. Finally, we asked patients
about the adherence to all of their medication, evaluation of
adherence to each individual medication is suggested for future
studies.
Possible Explanations and Comparison
With Other Studies
A systematic review (Santo et al., 2016) showed that the delivery
of an intervention, irrespective of its type, significantly improved
medication adherence (OR = 1.52; 95% CI, 1.25–1.86). Many
types of intervention components were implemented to improve
medication adherence in patients with IHDs including patient
education, counseling, intensified patient care, medication aids,
simplification of drug regimen reminders, financial incentives,
collaborative care, lay health mentoring, and direct observation
treatment. In terms of modes of delivery, the interventions
were delivered mostly by pharmacists, the others were nurses,
researchers, or two health care professionals (Santo et al., 2016).
Previous systematic reviews conducted to measure the effect
of pharmacists on the care of patients with CVDs (Koshman
et al., 2008; Santschi et al., 2011) and IHDs (Cai et al., 2013;
Kang et al., 2016) have shown a positive impact on patient
outcomes.
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We found no significant effects on quality of life which is
in line with previous studies (Community Pharmacy Medicines
Management Project Evaluation Team, 2007; Calvert et al., 2012).
Although a large proportion of all CVD events may be attributed
to poor adherence to cardiovascular medications (Brown and
Bussell, 2011; Chowdhury et al., 2013), we did not find a
significant difference in mortality and readmission to hospital
in our study, in line with some previous studies (Rinfret et al.,
2013; Castellano et al., 2014; Ho et al., 2014; Khonsari et al.,
2015). However, our study may have been too small and follow-
up too short to observe these effects. In a study (Choudhry et al.,
2011) the differences in clinical endpoints between full and usual
prescription coverage began to diverge after 12 months.
CONCLUSION
In conclusion, a pharmacist-led intervention improved
adherence to cardioprotective medications in patients with ACS
after hospital discharge, but not quality of life, mortality or
readmission to hospital. These results are promising but should
be tested in other settings prior to broader dissemination.
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